LUNG (Pulmonx) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


LUNG Pulmonx Corp LUNG
49 GF Score
Price $1.39
GF Value $7.13
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Pulmonx Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Pulmonx's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

LUNG vs LNSR, QTI, MDAI: Margin of Safety % (DCF FCF Based) Comparison

For the Medical Devices subindustry, Pulmonx's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulmonx Margin of Safety % (DCF FCF Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Pulmonx's Margin of Safety % (DCF FCF Based) falls into.


LUNG
49GF Score
Pulmonx Corp LUNG
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pulmonx (LUNG) Overvalued in 2026?

Based on GuruFocus' analysis, Pulmonx stock appears to be undervalued. The current stock price of $1.39 is trading 80.5% below its estimated GF Value™ of $7.13. GuruFocus considers Pulmonx to be Possible Value Trap.

Key valuation signals for LUNG:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $7.13 vs. price of $1.39 (80.5% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the LUNG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pulmonx Business Description

Other Exchanges 4NI:Germany
Address 700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
49GF Score

Get the complete analysis for LUNG

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.39
Price
$7.13
GF Value